- Home
- Browse
- National Institutes of Health
- RFA-HL-26-017
Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
- Deadline
- 2026-10-21
- 48 days left
- Award ceiling
- —
- Awards
- —
- Posted
- 2024-11-22
Summary
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and… […]
The rest of this announcement — free with an account
- →The full announcement text, not the first two sentences
- →All 4 review criteria reviewers score this against, extracted from this announcement
- →Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- →What similar funded projects received, from 219,000 past awards
No card required. Browsing and your first match are free.
More from National Institutes of Health
See all →NIH Director’s Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional)
The NIH Director's Transformative Research Award supports collaborative investigative teams or individual scientists who propose unusually bold and innovative research projects, which, if successful, would have a major impact in a broad area of relevance to the NIH.
3 review criteria on fileNIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileNIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileNIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileAlso in cardiovascular
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileAnimal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
Objective ORIP uses the P40 mechanism to support Animal and Biological Material Resource Centers in a variety of areas of biomedical science.
9 review criteria on fileNHLBI Program Project Applications (P01 Clinical Trials Optional)
The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health…
6 review criteria on fileOfficial announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-017.htmlSource: nih_guide+grants_gov. Always confirm dates with the funder.